In recent years, the widespread use of sodium/glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) in patients with heart failure has effectively improved the prognosis of patients with heart failure, but this study did not involve them, and the effects of SGLT2i and GLP-1 RA were not effectively evaluated [31–33]. Here, GLP1R is linked to heart failure.